Abstract 50P
Background
Breast Cancer is the most diagnosed cancer type worldwide and the second leading cause of cancer-related deaths among women. Anti-HER2 treatment has shifted the treatment paradigm of HER2-positive tumors. Historically, only breast cancer patients with HER2 IHC score of 3+ or with HER2 gene (FISH) amplification have benefited from anti-HER2 agents. However, emerging evidence suggests that even a minimal amplification of HER2 may significantly impact response to therapy and prognosis. This led to the introduction of the new concept of HER2-low breast cancers. Our retrospective analysis aims to unveil the impact of HER2 low expression on the response to neoadjuvant chemotherapy (NACT) in non-metastatic HER2-negative breast cancers.
Methods
All patients’ profiles with non-metastatic, HER2-negative breast cancers who received neo-adjuvant chemotherapy and underwent surgery between the 1st of January 2018 and the 30th of August 2022 were retrospectively reviewed. Patients were stratified into HER2-low and HER2-negative groups based on IHC score and FISH amplification. To compare the two study groups, patients’ response was clinically evaluated using surgical pathology reports. The primary endpoint was the response to NACT reported as the objective response rate (ORR) of HER2-low and HER2-negative tumors.
Results
Out of 262 patients, 236 patients had a response. Among the responders, 32 patients (14%) in the HER2-low group had a complete response compared to 4 patients (14%) in the HER2-negative group, OR 0.7 (95% CI:0.2 – 3), p-value= 0.6. While 132 patients (57%) and 17 patients (59%) had a partial response in the HER2-low and HER2-negative groups respectively, OR 0.7 (95% CI:0.2 – 2), p-value= 0.5. Across both groups, more patients with hormone-positive tumors had a response compared to hormone-negative tumors (p-value=0.01).
Conclusions
Preliminary results did not show any statistically significant impact of HER2 low expression on neoadjuvant chemotherapy response. Nonetheless, statistical significance was observed relative to hormone expression, in accordance with the published literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Research Center, Hamad Medical Corporation.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract